BeiGene Ltd. (49B) - Total Assets
Based on the latest financial reports, BeiGene Ltd. (49B) holds total assets worth €5.84 Billion EUR (≈ $6.83 Billion USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 49B cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
BeiGene Ltd. - Total Assets Trend (2016–2024)
This chart illustrates how BeiGene Ltd.'s total assets have evolved over time, based on quarterly financial data. Explore how much of BeiGene Ltd.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
BeiGene Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
BeiGene Ltd.'s total assets of €5.84 Billion consist of 67.4% current assets and 32.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 44.4% |
| Accounts Receivable | €676.28 Million | 11.4% |
| Inventory | €494.99 Million | 8.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €129.76 Million | 2.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how BeiGene Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BeiGene Ltd. market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BeiGene Ltd.'s current assets represent 67.4% of total assets in 2024, a decrease from 92.3% in 2016.
- Cash Position: Cash and equivalents constituted 44.4% of total assets in 2024, up from 21.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 11.4% of total assets.
BeiGene Ltd. Competitors by Total Assets
Key competitors of BeiGene Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
BeiGene Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 2.08 | 6.15 |
| Quick Ratio | 1.71 | 1.84 | 6.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.91 Billion | €2.03 Billion | €2.84 Billion |
BeiGene Ltd. - Advanced Valuation Insights
This section examines the relationship between BeiGene Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.05 |
| Latest Market Cap to Assets Ratio | 4.35 |
| Asset Growth Rate (YoY) | 2.0% |
| Total Assets | €5.92 Billion |
| Market Capitalization | $25.73 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BeiGene Ltd.'s assets at a significant premium (4.35x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: BeiGene Ltd.'s assets grew by 2.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BeiGene Ltd. (2016–2024)
The table below shows the annual total assets of BeiGene Ltd. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €5.92 Billion ≈ $6.92 Billion |
+1.99% |
| 2023-12-31 | €5.81 Billion ≈ $6.79 Billion |
-9.00% |
| 2022-12-31 | €6.38 Billion ≈ $7.46 Billion |
-26.22% |
| 2021-12-31 | €8.65 Billion ≈ $10.11 Billion |
+54.37% |
| 2020-12-31 | €5.60 Billion ≈ $6.55 Billion |
+247.38% |
| 2019-12-31 | €1.61 Billion ≈ $1.88 Billion |
-28.33% |
| 2018-12-31 | €2.25 Billion ≈ $2.63 Billion |
+114.98% |
| 2017-12-31 | €1.05 Billion ≈ $1.22 Billion |
+157.87% |
| 2016-12-31 | €405.81 Million ≈ $474.44 Million |
-- |
About BeiGene Ltd.
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the trea… Read more